Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review

Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ironwood Pharmaceuticals Inc (Ironwood) is a biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. Its major products include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults; Zurampic (lesinurad) and Duzallo (lesinurad and allopurinol), for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions including IBS-C or CIC in pediatrics, abdominal pain associated with IBS and uncontrolled gastroesophageal reflux disease. Its other product candidates are intended for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and specialty diseases, including sickle cell disease and achalasia. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc Key Recent Developments

Mar 11,2019 Ironwood Capital Group Opens in Milwaukee
Feb 13,2019 Ironwood Pharmaceuticals provides fourth quarter and full year 2018 investor update
Jan 28,2019 Ironwood announces filing of Form 10 registration statement in connection with planned business separation
Jan 24,2019 Ironwood Pharmaceuticals initiates phase 1 trial of IW6463

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 

List of Tables
List of Figures
Section 1 - About the Company
Ironwood Pharmaceuticals Inc - Key Facts
Ironwood Pharmaceuticals Inc - Key Employees
Ironwood Pharmaceuticals Inc - Key Employee Biographies
Ironwood Pharmaceuticals Inc - Major Products and Services
Ironwood Pharmaceuticals Inc - History
Ironwood Pharmaceuticals Inc - Company Statement
Ironwood Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ironwood Pharmaceuticals Inc - Business Description
Ironwood Pharmaceuticals Inc - Corporate Strategy
Ironwood Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Ironwood Pharmaceuticals Inc - Strengths
Ironwood Pharmaceuticals Inc - Weaknesses
Ironwood Pharmaceuticals Inc - Opportunities
Ironwood Pharmaceuticals Inc - Threats
Ironwood Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 11, 2019: Ironwood Capital Group Opens in Milwaukee
Feb 13, 2019: Ironwood Pharmaceuticals provides fourth quarter and full year 2018 investor update
Jan 28, 2019: Ironwood announces filing of Form 10 registration statement in connection with planned business separation
Jan 24, 2019: Ironwood Pharmaceuticals initiates phase 1 trial of IW6463
Jan 24, 2019: Ironwood Pharmaceuticals announces board of directors for Ironwood and Cyclerion, effective following separation
Jan 23, 2019: Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW6463 the First CNSpenetrant sGC Stimulator to Enter Clinical Trials
Jan 06, 2019: Ironwood Pharmaceuticals appoints Michael Shetzline, M.D., Ph.D. as chief medical officer
Jan 04, 2019: Ironwood Pharmaceuticals announces chief executive officers to lead Ironwood and Cyclerion, effective upon upcoming separation
Jan 03, 2019: Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESSÂ linaclotide Patent Litigation
Oct 08, 2018: Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables

Ironwood Pharmaceuticals Inc, Key Facts
Ironwood Pharmaceuticals Inc, Key Employees
Ironwood Pharmaceuticals Inc, Key Employee Biographies
Ironwood Pharmaceuticals Inc, Major Products and Services
Ironwood Pharmaceuticals Inc, History
Ironwood Pharmaceuticals Inc, Subsidiaries
Ironwood Pharmaceuticals Inc, Key Competitors
Ironwood Pharmaceuticals Inc, Ratios based on current share price
Ironwood Pharmaceuticals Inc, Annual Ratios
Ironwood Pharmaceuticals Inc, Annual Ratios (Cont...1)
Ironwood Pharmaceuticals Inc, Interim Ratios
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios


List Of Figures

Ironwood Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Ironwood Pharmaceuticals Inc, Ratio Charts
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
 


Ironwood Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Ironwood Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Ironwood Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

Rocket Pharmaceuticals Inc (RCKT) - Financial and Strategic SWOT Analysis Review

Rocket Pharmaceuticals Inc (Rocket Pharma), formerly Inotek Pharmaceuticals Corp is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapeutics for the treatment of glaucoma and

USD 300 View Report

Sunesis Pharmaceuticals Inc (VIRX) - Financial and Strategic SWOT Analysis Review

Sunesis Pharmaceuticals Inc (VIRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available